Menu
← Oncology Approval Tracker
FDA DECISION ·
Monjuvi + lenalidomide
tafasitamab-cxix + lenalidomide · MorphoSys US
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including disease arising from low-grade lymphoma, who were ineligible for autologous stem cell transplant.
LAMPGEN ANALYSIS
Why it matters
Added a CD19-directed antibody plus lenalidomide for transplant-ineligible patients under accelerated approval.
What research teams should watch
Document transplant ineligibility and coordinate oral lenalidomide controls with infusion and blood-count monitoring.
PRIMARY RECORDS